American Chemical Society (June 4, 2021) Metabolite mining of environmentally collected aquatic and marine microbiomes offers a platform for the discovery of new therapeutic lead molecules. Combining a pre-fractionated chromatography library with liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based molecular networking and biological assays, we isolated and characterized two new micro-peptins (1 and 2) along with the
Continue ReadingNature- biopharma deal makers (November 30, 2020) Biosortia is building the world’s largest library of microbiome-derived compounds for therapeutic and other applications, by leveraging the company’s microbial harvesting platform to sample and mine aquatic microbiomes at unprecedented scales with sustainable and environmentally friendly approaches. Biosortia is seeking partners interested in accessing compounds and chemistries to
Continue ReadingScience & Technology (May 13, 2020). At this point, the coronavirus (SARS-CoV-2 or COVID-19) needs no introduction. As the global medical community struggles to prepare and treat the coronavirus crisis, scientists are racing to find some way to treat, prevent, and/or slow down the spread of infection or mitigate its virulence.
Continue ReadingInsightsCare Magazine (December 29, 2019) “Biosortia Pharmaceuticals, which is on a mission to unlock the next frontier of chemistry for discovering new, groundbreaking drugs by enabling unprecedented access to microbiome chemistry”
Continue ReadingURI – Kingston Rhode Island (October 28, 2019) More medicines may be developed faster in the near future, thanks to new technology that harnesses the tiny particles that make drug development possible. Microorganisms grown in laboratories have been the starting point for many medicines we have today. However, many more microorganisms exist in nature that
Continue ReadingNews USA (October 9, 2019) – 11|KTVA More medicines may be developed faster in the near future, thanks to new technology that harnesses the tiny particles that make drug development possible. Microorganisms grown in laboratories have been the starting point for many medicines we have today. However, many more microorganisms exist in nature that can’t be
Continue ReadingSan Diego, California (September 10, 2019)/PRNewswire/ – Biosortia, a leader in the next frontier of drug discovery, accessing the enormous chemical and genomic potential of natural microbiomes, is pleased to announce the addition of leading metabolomics expert, Dr. John Ryals to the Board of Directors. “It is an honor to have Dr. Ryals join the Board
Continue ReadingColumbus, OH Ohio University Presentation (November 9, 2018)
Continue ReadingColumbus, OH (October 28, 2018) – Journal of Natural Products Biosortia Demonstrated Products Aquatic microbiomes contain novel chemistry. Novel chemistry previously undetectable & inaccessible. Biosortia has proven capability of accessing previously undetectable and inaccessible chemistry in volumes sufficient for drug discovery.
Continue ReadingAmerican Chemical Society and American Society of Pharmacognosy (May 30, 2018) Four new microcystin congeners are described including the first three examples of microcystins containing the rare doubly homologated tyrosine residue 2-amino-5-(4-hydroxyphenyl)pentanoic acid (Ahppa) (1–4). Large-scale harvesting and biomass processing allowed the isolation of substantial quantities of these compounds, thus enabling complete structure determination
Continue Reading